Carmel Capital Partners LLC Sells 4,835 Shares of IQVIA Holdings Inc. $IQV

Carmel Capital Partners LLC reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 32.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 10,043 shares of the medical research company’s stock after selling 4,835 shares during the quarter. IQVIA comprises 0.8% of Carmel Capital Partners LLC’s investment portfolio, making the stock its 27th largest position. Carmel Capital Partners LLC’s holdings in IQVIA were worth $1,908,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc raised its stake in shares of IQVIA by 6.3% in the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock valued at $171,000 after purchasing an additional 53 shares during the period. Private Trust Co. NA grew its holdings in shares of IQVIA by 12.5% during the second quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock worth $95,000 after buying an additional 67 shares in the last quarter. CVA Family Office LLC raised its position in IQVIA by 11.6% in the 3rd quarter. CVA Family Office LLC now owns 654 shares of the medical research company’s stock valued at $124,000 after buying an additional 68 shares during the last quarter. E Fund Management Co. Ltd. lifted its stake in IQVIA by 3.7% in the 2nd quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 74 shares in the last quarter. Finally, Harbor Capital Advisors Inc. grew its stake in shares of IQVIA by 2.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 2,795 shares of the medical research company’s stock worth $531,000 after acquiring an additional 78 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Mizuho set a $266.00 price target on shares of IQVIA in a research note on Friday, January 9th. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Evercore ISI raised their price objective on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. Finally, HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and upped their target price for the stock from $195.00 to $235.00 in a report on Thursday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $251.06.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Down 0.9%

IQVIA stock opened at $239.15 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The company’s 50-day moving average is $228.82 and its 200-day moving average is $205.11. The firm has a market capitalization of $40.73 billion, a PE ratio of 32.81, a P/E/G ratio of 2.46 and a beta of 1.36. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. The business had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. IQVIA’s revenue was up 5.2% on a year-over-year basis. During the same period last year, the business posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.